Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Beckman Coulter agreed to acquire DSL for ~$138M, calling the deal a way to 'broaden our immunoassay menu and strategically advance our already successful…
Industry coverage characterized the DSL purchase as a 'savvy' tuck-in that strengthened Beckman Coulter's immunoassay business by adding proprietary…
Management said DSL plus Agencourt were expected to add $40-$50M of incremental revenue in 2006, fitting the 10%+ consumables growth target and broadening the…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Beckman Coulter acquires DSL for $138M; specialty immunoassays for reproductive endocrinology and cardiovascular risk.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Beckman Coulter Inc. / Diagnostic Systems Laboratories Corporation (DSL) (this deal) | 2005 | $138M | — |
| Beckman Coulter Inc. / Lumigen Inc. | 2006 | $185M | 69 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| Yamanouchi Pharmaceutical / Fujisawa Pharmaceutical Co. Ltd. | 2005 | — | 92 |
| Sankyo Co., Ltd. / Daiichi Pharmaceutical Co., Ltd. | 2005 | $8.0B | 92 |
| Cephalon Inc. / Salmedix, Inc. | 2005 | $160M | 89 |
| Roche Holding AG / GlycArt Biotechnology AG | 2005 | $182M | 80 |
← Browse all deals · How we score deals
More: 2005 deals